SOUTH SAN FRANCISCO, Calif.
June 13, 2012
/PRNewswire/ -- diaDexus, Inc. (OTC QB: DDXS), a company focused on the development and commercialization of proprietary cardiovascular diagnostic products, today announced that
Robert J. Schott
, M.D., M.P.H., F.A.C.C., has been appointed to the position of vice president of medical affairs. Dr. Schott brings 30 years of medical experience to diaDexus, the majority as a practicing cardiologist, which will be highly relevant as the company continues to expand the market awareness of both the PLAC®
Test ELISA Kit and the PLAC® Test for Lp-PLA2 Activity, simple blood tests that aid in assessing risk for coronary heart disease (CHD), ischemic stroke and cardiovascular disease. Dr. Schott most recently served as medical director and the director of cardiometabolic research at the Profil Institute for Clinical Research.
"Dr. Schott is an important addition to our leadership team. His depth of knowledge, experience and relationships in the cardiology field will accelerate development of physician education programs necessary to drive awareness of our PLAC® blood tests. These diagnostics have a remarkable ability to help uncover a hidden risk of heart attack and stroke," stated
Brian E. Ward
, Ph.D., chief executive officer of diaDexus. "Dr. Schott's expertise will be instrumental not only in working closely with clinicians but also in supporting our reimbursement initiatives in order to maximize the value of our product portfolio for shareholders."
Dr. Schott joins diaDexus from
where he was director of cardiometabolic research at the Profil Institute for Clinical Research, which specializes in early phase clinical research in diabetes and cardiometabolic disease. Previously, Dr. Schott was the chairman of cardiology at Deborah Heart and Lung Center, and the vice president of medical affairs and chief of cardiology at Sutter Medical Center in
. Dr. Schott holds B.S., M.D. and M.P.H. degrees from the
University of Michigan
, where he trained in internal medicine. He trained in cardiology at the Massachusetts General Hospital and was a Burgher Fellow at the Harvard Medical School. He was previously affiliated with Berkeley Heart Labs, where he was the associate director of the Lipid Institute Medical Clinic and was also a research scientist at the Max Planck Institute for Experimental Cardiology in Bad Nauheim.
"I am very enthusiastic about joining diaDexus. I have used the PLAC test as a preventive cardiologist, and have long found this marker of vascular inflammation to be clinically useful in the effort to more fully characterize heart attack and stroke risk in the growing population of patients who are susceptible to vascular events," stated Dr. Schott. "The PLAC® Test ELISA kit is FDA-approved and is recognized as a test which is well-validated as a marker for the short-term risk of heart attack and stroke. As a cardiologist who has treated thousands of patients over the years, I very much look forward to increasing our awareness of all the available tools for the detection of diseases which are increasingly manageable, diseases that when undertreated frequently have consequences that are devastating."